We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Esketamine, an anaesthetic derived from Ketamine, was approved for use in treating patients with Major Depressive Disorder ... that is administered by nasal spray, can be beneficial within ...
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...
Background: Mood disorders are very common among adolescents and include mainly bipolar disorder (BD) and major depressive disorder (MDD), with overlapping depressive symptoms that pose a significant ...
Background Major depressive disorder is estimated by the WHO to affect more than 300 million people globally, making depression the leading cause of disability worldwide. Antidepressants are commonly ...
Hundreds of millions of people around the world live with major depressive disorder (MDD), making it the most commonly diagnosed mental disorder with numbers increasing annually. Past studies show ...
Hosted on MSN1mon
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionW EDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results